Imunon 過去の業績

過去基準チェック /06

Imunonの収益は年間平均-7%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19.3% 29.6%割合で減少しています。

主要情報

-7.0%

収益成長率

34.0%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-29.6%
株主資本利益率	-237.4%
ネット・マージン	n/a
前回の決算情報	30 Sep 2024

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

収支内訳

Imunon の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:IMNN 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 24	0	-19	8	11
30 Jun 24	0	-18	8	11
31 Mar 24	0	-19	8	12
31 Dec 23	0	-20	10	11
30 Sep 23	0	-28	11	12
30 Jun 23	0	-31	13	12
31 Mar 23	0	-31	14	14
31 Dec 22	1	-36	14	12
30 Sep 22	1	-27	12	0
30 Jun 22	1	-26	11	0
31 Mar 22	1	-26	11	0
31 Dec 21	1	-21	11	0
30 Sep 21	1	-20	10	0
30 Jun 21	1	-22	9	0
31 Mar 21	1	-22	9	0
31 Dec 20	1	-21	8	0
30 Sep 20	1	-22	7	0
30 Jun 20	1	-19	7	0
31 Mar 20	1	-20	8	0
31 Dec 19	1	-17	8	0
30 Sep 19	1	-8	9	0
30 Jun 19	1	-7	9	0
31 Mar 19	1	-10	10	0
31 Dec 18	1	-12	10	0
30 Sep 18	1	-22	9	0
30 Jun 18	1	-23	8	0
31 Mar 18	1	-20	6	-3
31 Dec 17	1	-21	6	0
30 Sep 17	1	-21	6	4
30 Jun 17	1	-22	6	8
31 Mar 17	1	-21	6	15
31 Dec 16	1	-22	7	15
30 Sep 16	1	-22	6	15
30 Jun 16	1	-20	6	13
31 Mar 16	1	-21	7	14
31 Dec 15	1	-22	7	15
30 Sep 15	1	-23	7	16
30 Jun 15	1	-26	8	17
31 Mar 15	1	-27	8	17
31 Dec 14	1	-25	9	15
30 Sep 14	1	-23	8	12
30 Jun 14	1	-20	7	10
31 Mar 14	1	-13	7	9
31 Dec 13	1	-13	7	9

質の高い収益: IMNNは現在利益が出ていません。

利益率の向上: IMNNは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: IMNNは利益が出ておらず、過去 5 年間で損失は年間7%の割合で増加しています。

成長の加速: IMNNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IMNNは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: IMNNは現在利益が出ていないため、自己資本利益率 ( -237.45% ) はマイナスです。

Imunon 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Recent updates

Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

New major risk - Market cap size

New major risk - Financial position

IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001

Imunon, Inc. to Report Q3, 2024 Results on Nov 07, 2024

IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary

Imunon, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5.5 million.

Price target decreased by 11% to US$9.75

Imunon, Inc. announced that it has received $10 million in funding

New major risk - Shareholder dilution

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial

Price target decreased by 17% to US$10.00

IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study

IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024

Imunon, Inc. to Report Q1, 2024 Results on May 13, 2024

Imunon, Inc., Annual General Meeting, Jun 12, 2024

Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101

Imunon, Inc. has withdrawn its Follow-on Equity Offering.

Imunon, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New minor risk - Share price stability

Imunon Receives Non-Compliance Notice From Nasdaq

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer

Imunon, Inc. Appoints Sebastien Hazard as Chief Medical Officer

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.87 loss in 3Q 2022)

Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer

IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer

Imunon, Inc. Appoints Patrick Ott to Its Scientific Advisory Board

Imunon, Inc. Appoints Sachet A. Shukla to Its Scientific Advisory Board

First half 2023 earnings released: US$1.28 loss per share (vs US$2.59 loss in 1H 2022)

New major risk - Financial position

IMUNON, Inc. Announces Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

Imunon, Inc. Announces the Retirement of Augustine Chow as Class I Member of the Board of Directors

New minor risk - Share price stability

First quarter 2023 earnings released: US$0.68 loss per share (vs US$1.82 loss in 1Q 2022)

Consensus EPS estimates upgraded to US$2.95 loss

Price target decreased by 19% to US$18.75

Imunon, Inc. Announces Separation of Nicholas Borys as Executive Vice President and Chief Medical Officer, Effective as of February 28, 2023

Imunon Appoints Corinne Le Goff as Chief Executive Officer

Imunon, Inc. Announces Board Changes

Price target decreased to US$24.00

Imunon Appoints James E. Dentzer to Its Board of Directors

Celsion changes name to Imunon (IMNN)

Celsion Corporation Completes Enrollment of the Phase I/Ii Ovation 2 Study with Gen-1 in Advanced Ovarian Cancer

Celsion Corporation Provides Update on the Progress Made in the Development of A DNA-Based Vaccine Using its PLACCINE Platform Technology

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

First half 2022 earnings: EPS and revenues exceed analyst expectations

Celsion Q2 2022 Earnings Preview

Insufficient new directors

Celsion Corporation Appoints Dr. Corinne Le Goff as President an Director

Celsion adds Moderna chief commercial officer as CEO

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Celsion Corporation, Annual General Meeting, Jun 13, 2022

Price target decreased to US$32.67

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial At 2022 Aacr Annual Meeting

Celsion Corporation has completed a Follow-on Equity Offering in the amount of $7.000004 million.

Price target decreased to US$41.00

Full year 2021 earnings: EPS misses analyst expectations

Celsion Corporation Reports Impairment for the Fourth Quarter Ended December 31, 2021

Celsion Corporation Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

Celsion Corporation announced that it expects to receive $28.5 million in funding

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

過去基準チェック /06